Our previous findings have shown that the percentage of PD-1 + T cells are increased in patients with hematologic malignancies [8, 9], and increased expression of PD-1 in T cells was reported as an independent adverse risk factor for treatment response and survival in acute myeloid leukemia (AML) [10]. Here, PDCD1 is linked to hematologic disorder.